Efficacy of Platelet-Rich Plasma (PRP) with Tadalafil and PRP Alone in the Treatment of Patients with Erectile Dysfunction (ED)

A comparative study between the effectiveness of platelet-rich plasma (PRP) combined with tadalafil and PRP alone in the treatment of patients with erectile dysfunction (ED)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250730066700N1

Enrollment

Registered

2025-08-09

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with erectile dysfunction.

Interventions

Intervention 1: First intervention group: Group A will receive platelets along with a daily dose of 5 mg of tadalafil for 12 weeks. Intervention 2: Second intervention group: Group B, which will recei

Eligibility

Sex/Gender

Male

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with erectile dysfunction between the ages of 20 and 50 years Failure to respond to treatment with phosphodiesterase 5 inhibitors(PDE5Is)

Exclusion criteria

Exclusion criteria: Patients with Peyronie's disease Patients taking psychotropic drugs and psychiatric medications Patients with a history of trauma to the penis Patients with a history of prostate surgery Patients with uncontrolled blood sugar and HBA1C above 7 Patients with sickle cell anemia Patients with smoking Patients with active, acute infection and testosterone dysfunction Patients with severe lipid profile disorders

Design outcomes

Primary

Measure	Time frame
Erection rate. Timepoint: All patients will be assessed using the IIEF-5 questionnaire at baseline, 4, 8, and 12 weeks after the intervention. Method of measurement: International Index of Erectile Function (IIEF) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Hatef Sadri

Ahvaz University of Medical Sciences

73rahimi.niloofar@gmail.com+98 61 3373 8138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026